Chief Medical Officer, Encoded Therapeutics
Salvador Rico, MD, PhD, on A Multi-Pronged Approach to Tackling Dravet Syndrome
The chief medical officer of Encoded Therapeutics discussed ETX101 gene therapy and other initiatives in the company’s overall Dravet program.
Tackling Dravet Syndrome With Gene Therapy
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the different initiatives the company is conducting in Dravet syndrome.
Activating SCN1A to Treat Dravet Syndrome
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the company’s gene therapy pipeline, including their lead program ETX101.